Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tazarotene Cream, 0.1 % Clear all

Conditions: Acne Vulgaris
Interventions: Adapalene Gel, 0.1%, Tazarotene Cream, 0.1%, Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 12
States / cities: San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more

Conditions: Acne Vulgaris
Interventions: Benzoyl peroxide gel, Clindamycin gel, Tazarotene cream, Vehicle gel, Vehicle cream; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more

Conditions: Acne Vulgaris
Interventions: Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Arlington Hts., Illinois

Conditions: Skin Carcinoma
Interventions: tazarotene, placebo; Drug · Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 3
States / cities: Oakland, California • New York, New York

Conditions: Sun-Damaged Skin, Retinoid Intolerance
Interventions: Tazorac, Dove Mild Cleanser, Dove Facial Moisturizer; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Tazorac®, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more

Conditions: Acne Vulgaris
Interventions: Dapsone, Tazarotene; Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fremont, California

Conditions: Acne Vulgaris
Interventions: Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 9 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Acne Vulgaris
Interventions: AGN-190168 Formulation 1, AGN-190168 Formulation 2, tazarotene gel 0.1%, tazarotene cream 0.1%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Acne Vulgaris
Interventions: CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more

Conditions: Acne Vulgaris
Interventions: DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%, Tazorac Vehicle Cream 0%; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 9 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer, Lentigo Maligna
Interventions: Imiquimod Cream, Tazarotene Cream 0.1%; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neoplastic Syndrome
Interventions: tazarotene; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 2
States / cities: Oakland, California • New York, New York

Conditions: Hand-foot Skin Reaction, Rash
Interventions: urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Adapalene; Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fremont, California

Search by objective public record fields.

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Dose Range Study of CD5789 in Acne Vulgaris

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Sorafenib-induced Hand- Foot Skin Reaction Treatment

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris